CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Aprepitant injectable emulsionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2179 Saline Placebo Wiki 1.00
drug2527 Tocilizumab Wiki 0.19

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D009369 Neoplasms, NIH 0.22
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0002664 Neoplasm HPO 0.22
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19

The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.

NCT04470622 COVID-19 Drug: Aprepitant injectable emulsion Drug: Saline Placebo

Primary Outcomes

Measure: Proportion of subjects alive and discharged from the hospital.

Time: 14 Days.

Secondary Outcomes

Measure: Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).

Time: 56 Days.

Measure: Time to discharge from hospital.

Time: 56 Days.

Measure: Change from Baseline in Interleukin 6 (IL-6).

Time: Days 7, 14, 28, 56.

Measure: Incidence of treatment-emergent adverse events.

Time: From signing ICF to Day 56.

No related HPO nodes (Using clinical trials)